<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\n
GLP-1 (Glucagon-like peptide 1)\u00a0agonists\u00a0are a\u00a0group of medicines\u00a0that are\u00a0being used to\u00a0treat\u00a0type 2 diabetes patients.\u00a0They mimic the action of the GLP-1 hormone\u00a0in the body\u00a0that is\u00a0involved in stimulating insulin secretion\u00a0(a hormone that reduces\u00a0sugar\u00a0levels in the blood) and inhibiting glucagon secretion (hormone which increase the\u00a0sugar\u00a0levels in the blood). These actions help in\u00a0maintaining\u00a0optimal\u00a0blood glucose levels\u00a0while also acting\u00a0as a regulator of food intake and appetite.\u00a0WHO added GLP-1 therapies to its Essential Medicines List in September 2025 for high-risk type 2 diabetes.\u00a0<\/p>\n\n\n\n
Later,\u00a0on\u00a0December 1,\u00a02025, WHO released\u00a0guidelines on the use of GLP-1 receptor\u00a0agonists<\/a><\/strong> \/GIP dual agonists\u00a0in long-term obesity management 1<\/a><\/sup>.\u00a0Even though there is a rapid production of GLP-1\u00a0medications\u00a0across the global market,\u00a0these are\u00a0expected to reach fewer than 10% of people who could benefit from the\u00a0treatment by 2030 2<\/a><\/sup>.\u00a0However,\u00a0with\u00a0the generic variants\u00a0coming up for\u00a0some GLP-1 medications, the outreach\u00a0could\u00a0increase.\u00a0\u00a0<\/p>\n\n\n\n
A generic drug is an approved copy of the brand drug\u00a0that\u00a0mimics\u00a0the branded drug in its safety, effectiveness, dosage and administration 3<\/a><\/sup>.\u00a0So, generic\u00a0GLP-1 medicines are\u00a0generally more cost-effective\u00a0brand alternatives\u00a0that are approved for use\u00a0in patients with type 2 diabetes 4<\/a><\/sup>.<\/p>\n\n\n\n
In this blog, we will cover the availability of generic\u00a0GLP-1 medicines, the difference between generic names and brand names,\u00a0their cost, and\u00a0the\u00a0possible risks and\u00a0reasons\u00a0behind\u00a0limitation of generic medications.\u00a0We will also discuss some alternatives to GLP-1 medications and share some tips on how to choose the right medication.\u00a0<\/p>\n\n\n\n
<\/p>\n\n\n\n
<\/span>Is There a Generic GLP-1 Available?<\/strong><\/span><\/h2>\n\n\n\n
GLP-1 medications for managing type 2 diabetes are commonly available under brand names Ozempic (semaglutide), Victoza (liraglutide) or Byetta (exenatide).\u00a0\u00a0<\/p>\n\n\n\n
Generic GLP-1 medications\u00a0are medicines which are approved\u00a0substitutes\u00a0for the branded medicines in action, effect,\u00a0strength, and mode of administration\u00a0as they\u00a0contain\u00a0the same active molecules.\u00a0\u00a0<\/p>\n\n\n\n
United States Food & Drug Administration has approved a generic variant\u00a0with the\u00a0active ingredient liraglutide and a generic variant of\u00a0the\u00a0active ingredient exenatide,\u00a0used\u00a0to improve blood sugar in type 2 diabetes patients 4<\/a><\/sup>.<\/p>\n\n\n\n
In India, generic\u00a0injectable\u00a0semaglutide drugs\u00a0have been approved by\u00a0CDSCO after the patent expiry of semaglutide\u00a0in\u00a0March 2026.\u00a0The manufacturers\u00a0of these\u00a0include Sun Pharma, Dr Reddy\u2019s, Natco and Glenmark, and the generic drugs came into action as a substitute for branded Ozempic 5<\/a><\/sup>.\u00a0Torrent Pharmaceuticals has also launched\u00a0the first\u00a0generic oral semaglutide\u00a0(Sembolic\/Semalix)9<\/a><\/sup>\u00a0in\u00a0India\u00a0alongside its injectable version\u00a0on\u00a0March\u00a021, 2026.\u00a0\u00a0<\/p>\n\n\n\n
<\/span>Generic GLP-1 Generic Names vs Brand Names<\/strong><\/span><\/h2>\n\n\n\nGLP-1 generic names\u00a0can vary based on the manufacturers, with the same active ingredient.\u00a0Here are some generic GLP-1 medications 5<\/a><\/sup>:<\/p>
<\/div>

Brand Name<\/strong>\u00a0<\/td>	Generic Name<\/strong>\u00a0<\/td>	Drug\u00a0Class<\/strong>\u00a0<\/td>	Drug Availability<\/strong>\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	Semanat\u00a0<\/a><\/strong><\/td>	Semaglutide:\u00a0GLP-1 receptor agonist\u00a0<\/td>	Multi-dose vial\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	GLIPIQ\u00a0<\/td>	Semaglutide:\u00a0GLP-1 receptor agonist\u00a0<\/td>	Vial-based\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	Obeda\u00a0<\/td>	Semaglutide:\u00a0GLP-1 receptor agonist\u00a0<\/td>	Pre-filled disposable pen\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	Sematrinity<\/a><\/strong><\/td>	Semaglutide:\u00a0GLP-1 receptor agonist\u00a0<\/td>	Multi-dose pen\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	Semaglyn\u00a0<\/td>	Semaglutide: GLP-1 receptor agonist\u00a0<\/td>	Reusable Pen\u00a0<\/td><\/tr>
Ozempic\u00a0<\/td>	Semanext\u00a0<\/td>	Semaglutide: GLP-1 receptor agonist\u00a0<\/td>	Pre-filled pen\u00a0<\/td><\/tr>
Victoza\u00a0<\/td>	Lirafit\u00a0<\/a><\/strong><\/td>	Liraglutide: GLP-1 receptor agonist\u00a0<\/td>	Pre-filled pen\u00a0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n <\/span>Common Side Effects Associated with\u00a0GLP-1<\/strong><\/span><\/h2>\n\n\n\n \n Gastrointestinal: <\/strong>nausea, vomiting, abdominal distension, constipation\u00a0<\/li>\n\n\n\n Rare warnings:<\/strong>\u00a0pancreatitis, gallstones, cholecystitis, acute kidney\u00a0injury<\/li>\n<\/ul>\n\n\n\n Contraindications<\/strong><\/h3>\n\n\n\n \n Medullary thyroid carcinoma^{19<\/a><\/sup><\/li>\n\n\n\n} Multiple endocrine neoplasia syndrome type 2\u00a0<\/li>\n\n\n\n Hypersensitivity\u00a0<\/li>\n\n\n\n Pregnancy and breastfeeding\u00a0<\/li>\n\n\n\n History of pancreatitis\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n This is why all GLP-1 formulations are classified under Schedule H\u00a0drugs\u00a0(prescription-only)\u00a0and over-the-counter sales are\u00a0strictly prohibited<\/em>.<\/strong>\u00a0<\/p>\n\n\n\n <\/span>Why Are Generic GLP-1 Medications Limited?<\/strong><\/span><\/h2>\n\n\n\n Generic GLP-1\u00a0drug applicants must prove\u00a0to\u00a0the\u00a0approving authorities\u00a0that the generic medicine is\u00a0the\u00a0same as the branded one.\u00a0Factors\u00a0limiting\u00a0the availability\u00a0of generic medications\u00a0can be:\u00a0<\/p>\n\n\n\n \n Generic drug\u00a0must\u00a0prove\u00a0its bioequivalence in terms of efficacy, safety, active ingredients, route of administration, and strength to their brand equivalent 6<\/a>,15<\/a><\/sup>.<\/li>\n\n\n\n The\u00a0GLP-1 drugs are complex peptide molecules\u00a0which\u00a0take\u00a0time to produce 7<\/a><\/sup>.<\/li>\n\n\n\n Regulatory\u00a0authorities\u00a0can take time\u00a0for thorough\u00a0review\u00a0of clinical bioequivalence of the generic drug 7<\/a><\/sup>.<\/li>\n\n\n\n Brand-name drugs are often protected by patents. So,\u00a0during\u00a0this period, brand-name drugs would be the only approved medicines that can\u00a0be sold\u00a0exclusively. This can\u00a0prevent generic drug manufacturers\u00a0from\u00a0producing and marketing the drugs until the patent\u00a0expires 6<\/a><\/sup>.<\/li>\n\n\n\n The\u00a0mode of\u00a0delivery\u00a0of GLP-1\u00a0medications such as\u00a0pens, vials etc may have separate patents.\u00a0These\u00a0may further limit the\u00a0availability\u00a0of\u00a0generic drugs.\u00a0\u00a0<\/li>\n<\/ul>\n\n\n\n <\/span>Generic GLP-1 Cost<\/strong><\/span><\/h2>\n\n\n\n\n Generic injectable semaglutide in vial formats\u00a0possesses\u00a0the lowest cost. The weekly cost can range from\u00a0approximately Rs. 220 to Rs 450 per injection.\u00a0Prices can vary based on the strengths, pack\u00a0sizes,\u00a0and brands.The\u00a0weekly cost of generic injectable semaglutide in pen format can vary from\u00a0approximately Rs. 440 to Rs 20,305.\u00a0The prices can vary based on the brands.\u00a0These prices are moving fast; Semaglutide\u2019s\u00a0Indian\u00a0market share rose from 25% to 33% in a single month, as per recent reports.\u00a0<\/li>\n\n\n\n Liraglutide<\/a><\/strong>-containing generic medicines cost ranges\u00a0from Rs. 1820-8200. Prices can vary based on the strength,\u00a0sizes,\u00a0and brands.\u00a0<\/li>\n<\/ul>\n\n\n\n Note:<\/strong>\u00a0Generic GLP-1 prices in India have fallen steadily since the March 2026 patent expiry and launch of generics, as more\u00a0manufacturers\u00a0have entered the market. The figures above are reported as of August 2026 and may continue to change;\u00a0readers should confirm pricing with their pharmacy or the manufacturer before purchase.\u00a0\u00a0<\/em><\/p>\n\n\n\n The generic medicines<\/a><\/strong>\u00a0are considered the cheaper versions of branded drugs. However, certain situations can\u00a0cause\u00a0generic manufacturers to increase the prices of drugs 10<\/a><\/sup>:<\/p>\n\n\n\n \n For some generic drugs, it might not attract multiple producers.\u00a0<\/li>\n\n\n\n When a first generic drug\u00a0is brought\u00a0to the market, the manufacturer might face some difficulties and expenses.\u00a0<\/li>\n\n\n\n In\u00a0the\u00a0pharmaceutical industry, if\u00a0there is\u00a0any market consolidation,\u00a0the\u00a0number of manufacturers decreases.\u00a0<\/li>\n\n\n\n Unanticipated safety issues can reduce the supply of a generic drug.\u00a0<\/li>\n\n\n\n A\u00a0generic\u00a0manufacturer is obliged to\u00a0demonstrate\u00a0that it is the substitute of the branded product. If only one company produces a medicine and\u00a0controls\u00a0the distribution, other companies might face difficulty in collecting samples of the original drug.\u00a0<\/li>\n<\/ul>\n\n\n\n <\/span>Risks of Buying Cheap GLP-1 Medicines<\/strong><\/span><\/h2>\n\n\n\nWith several generics\u00a0flooding\u00a0the market, the chances of having a counterfeit product\u00a0are\u00a0also\u00a0high.\u00a0These may have too little or too much\u00a0of the active ingredient or even wrong ingredients.\u00a0The use of cheap\u00a0or counterfeit\u00a0GLP-1 medicines can be associated with\u00a0several potential health risks, which can\u00a0include 11<\/a><\/sup>:<\/p>\n\n\n\n \n Decreased Effectiveness<\/strong>: Insufficient active ingredient in the drugs may result\u00a0in\u00a0ineffective results in the treatment\u00a0of\u00a0type 2 diabetes and\u00a0weight\u00a0loss.\u00a0<\/li>\n\n\n\n Unknown Ingredients<\/strong>: Since the composition might be unknown in these drugs, unpredictable\u00a0side effects\u00a0or other drug interactions might result.\u00a0<\/li>\n\n\n\n Contamination<\/strong>: Drugs that are produced in\u00a0a\u00a0non-sterile environment may lead to the risk of contamination by other microorganisms. These can put the patient at an increased risk of mild infections to life-threatening complications.\u00a0<\/li>\n\n\n\n Incorrect ingredients<\/strong>: This can lead to complications related to underdosing or overdosing. The effects can range\u00a0from mild to even serious, life-threatening\u00a0health situations.\u00a0<\/li>\n<\/ul>\n\n\n\n <\/span>How to Choose the Right GLP-1 or Alternative<\/strong><\/span><\/h2>\n\n\n\nChoosing\u00a0the\u00a0right GLP-1 medicines\u00a0depends\u00a0on your major concerns, medical history, side effects<\/a><\/strong>12<\/a><\/sup>\u00a0and cost.\u00a0<\/p>\n\n\n\n 1. Main Use<\/strong><\/h3>\n\n\n\nMost GLP-1 medicines are helpful in type-2 diabetes cases. However, their action\u00a0gets\u00a0better when taken along with healthy lifestyles such as regular exercise and\u00a0a\u00a0healthy diet.\u00a0If,\u00a0along with diabetes, weight loss is also a\u00a0concern,\u00a0CDSCO-approved brands of\u00a0GLP-1 medicines like\u00a0Ozempic\/generic Semaglutide and Mounjaro (tirzepatide)\u00a0are recommended 1<\/a><\/sup>.<\/p>\n\n\n\n 2. Associated Health Conditions<\/strong><\/h3>\n\n\n\nYour doctor might also check other health conditions and can suggest appropriate medicines.\u00a0Semaglutide\u00a0(SELECT trial)\u00a0alongside\u00a0Dulaglutide and Liraglutide are the approved medicines for the treatment\u00a0of\u00a0diabetes patients who\u00a0have\u00a0heart problems 17<\/a>,18<\/a><\/sup>.\u00a0Semaglutide (Ozempic) based on the FLOW trial, has approval for proven kidney protection\u00a0in people with Type-2 DM 1<\/a>,16<\/a><\/sup>.\u00a0Your healthcare provider can better choose the most suitable medication for you\u00a0based on your health needs.\u00a0<\/p>\n\n\n\n 3. Injections or Tablets<\/strong><\/h3>\n\n\n\nFor semaglutide, it is available both as tablets\u00a0and\u00a0injections. People who are afraid\u00a0of\u00a0injections can consider the option of pills 12<\/a><\/sup>.\u00a0However, only your\u00a0doctor\u00a0can advise the appropriate medicine suitable for you based on your health conditions.\u00a0<\/p>\n\n\n\n 4. Concerns of Side Effects<\/strong><\/h3>\n\n\n\nMost of the side effects happen\u00a0due to beginning of treatment and when\u00a0dose\u00a0is increased,\u00a0and these\u00a0improve\u00a0as the body gets\u00a0adjusted to the treatment 12<\/a><\/sup>.\u00a0If you are concerned about the side effects, discuss with your doctor about which.\u00a0Choosing the best GLP-1 agonist based on your health condition can only be done by a doctor.\u00a0<\/p>\n\n\n\n 5. Cost Factors<\/strong><\/h3>\n\n\n\nThese medicines\u00a0need\u00a0to\u00a0be taken\u00a0for\u00a0the long term,\u00a0and these possess high costs ^{8<\/sup>.<\/a>\u00a0These factors can\u00a0be discussed\u00a0with your healthcare provider for better options.\u00a0<\/p>\n\n\n\n} These are the points you need to consider before selecting a GLP-1 medicine; however, your doctor is the only person who can assess your health conditions, your specific concerns,\u00a0and the\u00a0concerned side\u00a0effects\u00a0and\u00a0suggest the appropriate medicine\u00a0accordingly. Self-medication might be dangerous to your health.\u00a0<\/p>\n\n\n\n *Also Read:* *Why Should Doctors Prescribe Generic Drugs? Advantages & Disadvantages\u00a0<\/a><\/em><\/strong><\/p>\n\n\n\n* <\/span>Conclusion<\/strong><\/span><\/h2>\n\n\n\n Generic GLP-1 medications\u00a0are the affordable substitutes of the branded drugs,\u00a0which should be\u00a0the\u00a0same in their ingredients, strength, dosages and mode of administration.\u00a0In India, GLP-1 drugs are advised to be used only by the prescription of\u00a0a doctor.\u00a0It is important to choose the right medication, even in generics, as counterfeit products can\u00a0be dangerous to health.\u00a0<\/p>\n\n\n\n <\/span>Frequently Asked Questions (FAQs)<\/strong><\/span><\/h2>\n\n\n\nWhat is the difference between Ozempic and generic GLP-1?<\/strong><\/strong> Ozempic is a Brand name, which\u00a0contains\u00a0the active\u00a0ingredient semaglutide and is a GLP-1 receptor agonist used to control blood sugar in type 2 diabetes patients 13<\/a><\/sup>.\u00a0Generic GLP-1 medicine\u00a0is\u00a0a\u00a0cost-effective\u00a0substitute for\u00a0brand-name medicines\u00a0in their dosage, safety, effectiveness and mode of taking 6<\/a><\/sup>.<\/p> <\/div> What is the poor man\u2019s alternative to Ozempic?<\/strong><\/strong> Ozempic is the brand name for the injectable semaglutide drug, and it has a high cost. In India,\u00a0now\u00a0generic\u00a0semaglutide is available\u00a0which\u00a0is at a\u00a0lower cost compared to branded Ozempic. It can\u00a0be found under\u00a0names like\u00a0Noveltreat, Obeda, Sematrinity and Semanext<\/p> <\/div> Why is GLP-1 so expensive?<\/strong><\/strong> Ozempic is the brand name for the injectable semaglutide drug, and it has a high cost. In India,\u00a0now\u00a0generic\u00a0semaglutide is available\u00a0which\u00a0is at a\u00a0lower cost compared to branded Ozempic. It can\u00a0be found under\u00a0names like\u00a0Noveltreat, Obeda, Sematrinity and Semanext 5<\/a><\/sup>.<\/p> <\/div> Can I switch directly from a branded GLP-1 medicine to a generic one?<\/strong><\/strong> Yes, but switching between a branded and generic GLP-1 medicine should only be done under your doctor\u2019s guidance. Your doctor can confirm the correct dose, device type, and monitoring needed during the switch, since pen mechanisms and dose-adjustment steps can vary between brands.<\/p> <\/div> Do I need a prescription to buy generic GLP-1 medicines in India?<\/strong><\/strong> Yes. GLP-1 medicines, including generic versions, are classified as Schedule H drugs under India\u2019s Drugs and Cosmetics Rules, 1945, and can only be sold against a valid prescription from a registered medical practitioner. Buying them without a prescription is not\u00a0permitted 14<\/a><\/sup>.\u00a0<\/p> <\/div> <\/div>\n\n\n\n <\/span>Reference<\/strong><\/span><\/h2>\n\n\n\n1. GLP-1 agonists: MedlinePlus Medical Encyclopedia. Accessed August 3, 2026. https:\/\/medlineplus.gov\/ency\/article\/007853.htm\u00a0<\/a><\/p>\n\n\n\n 2. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. Accessed August 4, 2026. Available from: https:\/\/www.who.int\/news\/item\/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity<\/a>\u00a0<\/p>\n\n\n\n 3. Research C for DE and. Generic Drugs: Questions & Answers.\u00a0FDA<\/em>. Published online June 8, 2026. Accessed August 4, 2026. https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drugs-questions-answers<\/a>\u00a0<\/p>\n\n\n\n 4. Commissioner O of the. FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes. FDA. December 27, 2024. Accessed August 3, 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes\u00a0<\/a><\/p>\n\n\n\n 5. Menon DRM, MD. Generic Semaglutide India 2026: Brands, Prices, Cost \| DermaVue. DermaVue Skin & Hair Clinics. April 7, 2026. Accessed August 6, 2026. Available from: https:\/\/dermavue.com\/medical-weight-loss\/generic-glp1-india\/\u00a0<\/a><\/p>\n\n\n\n 6. Research C for DE and. Generic Drug Facts.\u00a0FDA<\/em>. Published online June 2, 2026. Accessed August 3, 2026. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drug-facts\u00a0<\/a><\/p>\n\n\n\n 7. Research C for DE and. What Is the Approval Process for Generic Drugs?\u00a0FDA<\/em>. Published online September 16, 2025. Accessed August 3, 2026. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/what-approval-process-generic-drugs\u00a0<\/a><\/p>\n\n\n\n 8. Paddu NU, Lawrence B, Wong S, Poon SJ, Srivastava G. Weight maintenance on cost\u2010effective antiobesity medications after 1\u2009year of GLP\u20101 receptor agonist therapy: a real\u2010world study.\u00a0Obes Silver Spring Md<\/em>. 2024;32(12):2255-2263. doi:10.1002\/oby.24177. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39558626\/<\/a><\/p>\n\n\n\n 9. Regalla DKR, Patel P. Oral Antidiabetic Medications. In:\u00a0StatPearls<\/em>. StatPearls Publishing; 2026. Accessed August 3, 2026. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482386\/<\/a>\u00a0<\/p>\n\n\n\n 10. Torreele E. Why are our medicines so expensive? Spoiler: Not for the reasons you are being told. Eur J Gen Pract. 2024;30(1):2308006. doi:10.1080\/13814788.2024.2308006. PMID: 38299574; PMCID: PMC10836477. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10836477\/<\/a><\/p>\n\n\n\n 11. Semaglutide injection products. Accessed August 4, 2026. Available from: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/semaglutide-injection-products\u00a0<\/a><\/p>\n\n\n\n 12.\u00a0Kalra S. Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered\u00a0Approach. Diabetes Ther. 2014 Jun;5(1):333-40. doi: 10.1007\/s13300-014-0058-y. Epub 2014 Feb 19.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24549850\/<\/a><\/p>\n\n\n\n 13. OZEMPIC. Accessed August 4, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/209637s038lbl.pdf<\/a><\/p>\n\n\n\n 14. Government of India, Ministry of Health and Family Welfare. The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 (as amended up to 31st December 2016) [Internet]. New Delhi: Central Drugs Standard Control Organization; 2016 [cited 2026 Aug 13]. Available from: https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/acts_rules\/2016DrugsandCosmeticsAct1940Rules1945.pdf<\/a><\/p>\n\n\n\n 15.\u00a0Elsevier. Bioequivalence \u2013 an overview \| ScienceDirect Topics [Internet]. Amsterdam: Elsevier; [cited 2026 Aug 13]. Available from: https:\/\/www.sciencedirect.com\/topics\/biochemistry-genetics-and-molecular-biology\/bioequivalence<\/a><\/p>\n\n\n\n 16.\u00a0Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056\/NEJMoa2403347. Epub 2024 May 24. PMID: 38785209. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38785209\/\u00a0<\/a><\/p>\n\n\n\n 17. American College of Cardiology. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) [Internet]. Washington (DC): American College of Cardiology; 2024 Sep 12 [cited 2026 Aug 13]. Available from: https:\/\/www.acc.org\/latest-in-cardiology\/clinical-trials\/2023\/11\/09\/15\/04\/select\u00a0<\/a><\/p>\n\n\n\n 18.\u00a0Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056\/NEJMoa2307563. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2307563\u00a0<\/a><\/p>\n\n\n\n 19.\u00a0U.S. Food and Drug Administration. WEGOVY (semaglutide) injection, for subcutaneous use: prescribing information [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2023 Jul [cited 2026 Aug 13]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf\u00a0<\/a><\/p>\n\n\n\n Disclaimer: <\/strong>The information provided here is for educational\/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.<\/em><\/p>\n\n\n\n Links and product recommendations in the information provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products\/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.<\/em><\/p>\n<\/body><\/html>\n *\r\n* \r\n \r\n $\"Likes\"$ \r\n <\/a>\r\n <\/span>\r\n<\/div> \r\n \r\n $\"Dislikes\"$ \r\n <\/a>\r\n <\/span>\r\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Introduction GLP-1 (Glucagon-like peptide 1)\u00a0agonists\u00a0are a\u00a0group of medicines\u00a0that are\u00a0being used to\u00a0treat\u00a0type 2 diabetes patients.\u00a0They mimic the action of the GLP-1 hormone\u00a0in the body\u00a0that is\u00a0involved in stimulating insulin secretion\u00a0(a hormone that reduces\u00a0sugar\u00a0levels in the blood) and inhibiting glucagon secretion (hormone which increase the\u00a0sugar\u00a0levels in the blood). These actions help in\u00a0maintaining\u00a0optimal\u00a0blood glucose levels\u00a0while also acting\u00a0as a regulator [\u2026]","protected":false},"author":201,"featured_media":285726,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[14037,10684],"tags":[14681,14682,14683,14684],"acf":[],"_embedded":{"wp:featuredmedia":[{"source_url":"https:\/\/pharmeasy.in\/blog\/wp-content\/uploads\/2026\/08\/generic-glp1.webp"}]},"_links":{"self":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/285627"}],"collection":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/users\/201"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/comments?post=285627"}],"version-history":[{"count":6,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/285627\/revisions"}],"predecessor-version":[{"id":285737,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/285627\/revisions\/285737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media\/285726"}],"wp:attachment":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media?parent=285627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/categories?post=285627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/tags?post=285627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}